GALT (Galectin Therapeutics, Inc.) יחס שווי שוק לשווי בספרים

Galectin Therapeutics (GALT) is optimizing plant polymer supply chains to combat fibrosis while maintaining high profitability. The company is developing belapectin, a promising drug for NASH therapy, which is reflected in the price action at -1.62. Simultaneously, the business is implementing ESG standards, reducing harmful laboratory emissions and investing in the energy efficiency of office spaces to protect the environment.

Finding a balance between asset value and market price requires an analysis of the market-to-book ratio, which determines the degree of business overvaluation relative to its book value. For Galectin Therapeutics (GALT), which is scaling final tests for belapectin, changes in the market capitalization-to-book multiple reflect a speculative premium on assets in anticipation of a monopoly in liver cirrhosis therapy.